City Therapeutics, Inc. CTY
Regular-session close
After hours · Nov 20, 4:00 PM ET
- YTD
- -13.75%
- 1 year
- -13.75%
Held by funds
11 US ETFs and mutual funds hold CTY · largest positions
Ownership
- Institutions 50.9%
- Insiders 7.37%
- Public and other holders 41.7%
Top institutional holders
No holders on record
Top mutual fund holders
No holders on record
Included in Plus and up
Sign in to see Institutional ownership
How much funds own from their 13F filings, quarter by quarter, and the largest holders.
Free with an account
Sign in to see Insider activity
Two years of insider buying and selling by month, marked on the price.
Included in Plus and up
Sign in to see Congress trading
Every stock trade disclosed by members of the US Senate and House.
Leadership team
Who runs CTY, and what each was last paid
Andrew C. Orth, President, CEO & DirectorAverage age 56
| Name | Title | Pay | Age |
|---|---|---|---|
| Andrew C. Orth | President, CEO & Director | $677K | 56 |
| Tracy Zimmermann | Chief Scientific Officer | $667K | 56 |
| Baisong Mei | Chief Medical Officer | $528K | 62 |
| John Michael Maraganore | Co-Founder & Executive Chair | $200K | 64 |
| Ari Nowacek | Co-Founder & SVP of Corporate Development | — | — |
| Kotaro Nakanishi | Co-Founder & Scientific Advisor | — | — |
| Phillip D. Zamore | Co-Founder & Scientific Advisor | — | — |
| Yukihide Tomari | Co-Founder & Scientific Advisor | — | — |
| Mark T. Keating | Co-Founder & Scientific Advisor | — | — |
| Keith C. Regnante | Chief Financial Officer | — | 56 |
| Sebastian Trousil | Co-Founder & COO | — | 42 |
Pay is the latest total FMP has for each person (salary, bonus, stock and other awards) and can lag the newest proxy statement. Source: Financial Modeling Prep, from the company’s SEC filings.
Free with an account
Sign in to see CEO compensation
What the chief executive was paid each year, by salary, bonus and stock, beside the company's earnings.
Free with an account
Sign in to see Board of directors
Who sits on the board, who chairs it, and how long each director has served.
Insiders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARCH VENTURE PARTNERS XII, LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 18, 2026 | 0 |
| MARAGANORE JOHN M | Director | Conversion of Exercise of derivative security | Oct 18, 2026 | 2,107,710 |
